New $400 million JPMorgan receivables facility
HIMS rose about 33% in June, and the current price (intraday $37.36, up 7.8%) is well above the average sell-side target of $29 and closing in on Canaccord's $40, the highest on the Street. The rally has been driven by enthusiasm over Novo volumes, a short squeeze, a technical breakout and analysts chasing the price, not by results.
Read more
The real binary event is the FDA peptide advisory committee on 23-24 Jul. It is shaping up as a clash between a supportive committee and an opposing briefing from FDA scientists, and the legitimacy of the process carries tail risk. The $400 million JPMorgan receivables facility disclosed in an 8-K filed with the SEC on 1 Jul is a neutral-to-positive liquidity tool (not new debt). It adds firepower for international expansion once Eucalyptus is consolidated, and for peptide capacity. Risk/reward at the current price leans unfavourable: limited upside on good news, a big drawdown if things go wrong.
Key evidence
- SEC 8-K (filed 1 Jul, hims-20260626.htm): subsidiaries XeCare LLC and Apostrophe Pharmacy LLC signed a receivables purchase agreement (RPA) with JPMorgan
- The RPA is capped at $400 million, with an initial 364-day term renewable indefinitely; eligible receivables are sold at a discount for cash
- Amendment No. 4 to the existing revolving credit facility, made at the same time, permits the arrangement; the parent guarantees performance but not collectability
- Nature of the financing: a working-capital tool that adds no on-balance-sheet debt and no equity dilution, building a funding runway for international expansion and peptide capacity
- Canaccord Genuity (Maria Ripps) raised its target from $32 to $40 and kept Buy. That implies only about 15% upside and is the highest target on the Street
- BofA (Allen Lutz) raised its target from $25 to $36 and kept Neutral. An $11 increase in one go is rare, but the target is still below the current price
Show 5 more
- Leerink kept Market Perform and its $25 target unchanged
- The average target across 13 analysts rose from $28.42 to $29.27, with a range of $21-40
- The $29 average consensus target implies about 16% downside from the current price
- Up about 33% in June; this rally is sentiment, a short squeeze, technicals and chasing, not results
- 23-24 Jul FDA peptide advisory committee: a supportive committee against an opposing briefing from FDA scientists (the briefing came out yesterday)
Catalysts to watch
- 23-24 Jul FDA peptide advisory committee: the decisive binary event
- Progress on international expansion once Eucalyptus is consolidated
- Q2 results (the shift from compounded to branded weight-loss drugs, plus credit card spending data)
- Peptide capacity ramp-up
Risks
- The FDA committee goes wrong: challenges to the legitimacy of the process, while the scientists' opposing briefing could narrow the scope of any approval
- The current price already reflects most of a peptide approval, so upside on good news is limited (Canaccord's top target of $40 implies only 15%)
- The $29 average consensus target implies 16% downside; if sentiment turns, the drawdown could be large
- Enthusiasm over Novo volumes could fade and the short squeeze could reverse
- The receivables financing is neutral, but the discount rate needs watching for what it signals about receivables quality
Sources (5)
- SEC EDGAR 8-K (hims-20260626.htm, filed 1 Jul)
- Canaccord Genuity (Maria Ripps)
- Bank of America (Allen Lutz)
- Leerink Partners
- Sell-side consensus data (13 analysts)
A brief is a lead for our research, not a verified conclusion or advice.